ENTERO Entero Healthcare Solutions Q2 FY26 results (Jul–Sep 2025) and concall
Entero Healthcare Solutions delivered a strong Q2 FY26, marked by robust revenue growth, significant margin expansion, and improved working capital efficiency. The company is aggressively expanding its MedTech segment through strategic acquisitions, which are expected to further boost margins and growth. Management reiterated its FY26 guidance, confident in achieving targets despite H1 delays, driven by organic initiatives and the full impact of recent acquisitions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 20.8%, net profit up 42.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 1,301 | 1,359 | 1,339 | 1,404 | 1,571 +21% |
| EBITDA | 42 | 50 | 49 | 50 | 62 +48% |
| Net profit | 26 | 29 | 31 | 30 | 37 +42% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
